Blood Biomarker Panel for Alzheimer Disease, PrecivityAD2™, LucentAD™ Complete
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, accounting for 60–80% of cases. It is characterized by abnormal deposits of amyloid-β plaques and tau tangles, which impair neuronal function and ultimately lead to cognitive decline. While cerebrospinal fluid (CSF) and amyloid PET imaging remain reference standards, they are invasive, costly, or less accessible. Blood-based biomarker testing offers a minimally invasive alternative.
The PrecivityAD2™ test measures the amyloid beta 42/40 ratio (Aβ42/40) along with Apolipoprotein E prototype (equivalent to ApoE genotype) using C₂N’s proprietary mass spectrometry platform. Clinical validation studies demonstrate sensitivity of 88% and specificity of 89%, with an AUC-ROC of 0.94, supporting its reliability in predicting amyloid plaque presence.
The LucentAD™ Complete test expands biomarker coverage by quantifying five proteins relevant to AD pathophysiology: phosphorylated tau 217 (p-Tau217), amyloid beta 1-40 (Aβ40), amyloid beta 1-42 (Aβ42), glial fibrillary acidic protein (GFAP), and neurofilament light chain (Nf-L). An algorithm integrates these values into an Amyloid Risk Score (0–100) to classify results as Low, Intermediate, or High likelihood of amyloid pathology.
Together, these tests provide clinicians with accurate, scalable tools for evaluating patients with cognitive symptoms where AD is suspected.
- As an aid in the diagnosis of Alzheimer’s disease in symptomatic individuals
- Aid in differential diagnosis of dementia from Alzheimer’s disease
- Helpful in investigating other neurodegenerative conditions
PrecivityAD2™:
Positive: High likelihood of brain amyloid pathology.
Negative: Low likelihood of amyloid pathology.
LucentAD™ Complete Amyloid Risk Score:
<45: Low likelihood of amyloid pathology.
45–70: Intermediate likelihood; may require confirmatory CSF or PET testing.
70: High likelihood of amyloid pathology.
Note: A positive result suggests amyloid pathology but does not alone establish a diagnosis of AD. Results must be interpreted with clinical context.
| Test | Result / Interpretation |
| PrecivityAD2™ | Negative |
| LucentAD™ Complete Amyloid Risk Score (0-100) | <45: Low Likelihood of amyloid pathology |
| 45-70: Intermediate likelihood | |
| >70: High likelihood |
Specimen collection and handling: Whole blood, EDTA.
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: 30 days
- Alzheimers Dement. 2024 May;20(5):3179-3192. [PMID: 38491912]
- J Alzheimers Dis Rep. 2023 May 3;7(1):355-380. [PMID: 37220625]
- JAMA. 2024 Oct 15;332(15):1245-1257. [PMID: 39068545]
- Alzheimers Dement. 2025 Mar;21(3):e14570. [PMID: 40108829]
- Diagnostics (Basel). 2024 Aug 10;14(16):1739. [PMID: 39202226]